BuSpar
(Buspirone)ApprovedSmall molecule
Bristol-Myers SquibbBuspirone is used to treat anxiety disorders and help reduce feelings of worry and nervousness. It works by affecting certain chemicals in the brain that control mood and anxiety.[2] BuSpar is currently approved and in use across 21 indications[4].[1]
BuSpar is one of 420 small molecule programs targeting Major Depressive Disorder. It is currently in Approved.
21
Indications
48
Total Trials
6
Active Trials
419
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 21 indications
Competition
Competitive Landscape
120 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1BuSpar
Bristol-Myers SquibbApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Aticaprant
Johnson & JohnsonPhase 3
Selective Serotonin Reuptake Inhibitor
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment5 trials
Autism Spectrum Disorder4 trials
Cocaine Dependence2 trials
Brain Injury2 trials
34 more indications
Age1 trial
Sleep Apnea1 trial
Amantadine1 trial
Clinical Trial1 trial
Vertigo1 trial
Effectiveness1 trial
Epilepsy1 trial
Buspirone Therapy for Localized Epilepsy
Terminated·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT01496612·9 enrolled
Stroke1 trial
Major Depression1 trial
Generalized Anxiety Disorder1 trial
Concentration1 trial
Neuromodulation1 trial
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES
Completed·—·Phase 1·NCT04052776·3 enrolled
Function1 trial
Opioid Use Disorder1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Sep 29, 1986
BUSPAR
NDA NDA018731
Dec 20, 2000
BUSPAR
NDA NDA021190
Sources
References
- [1]
- [2]MedlinePlus Drug Information — BuSpar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Buspirone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 1a (5-Ht1a) Receptor Partial Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company